isoxazoles has been researched along with Hypertrophy in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Du, L; Han, C; Li, X; Qin, A; Zhang, K; Zhao, C; Zhao, J; Zhou, T | 1 |
| Dartevelle, P; Eddahibi, S; Fadel, E; Humbert, M; Izziki, M; Mercier, O; Sage, E | 1 |
| Cross, DM; Derzi, M; Horsley, E; Owen, K; Stavros, FL | 1 |
| Block, N; Brock, TA; Chen, SJ; Chen, YF; Dixon, RA; Munsch, CL; Sherwood, SJ; Tilton, RG; Wu, C | 1 |
4 other study(ies) available for isoxazoles and Hypertrophy
| Article | Year |
|---|---|
Lysophosphatidic Acid Induces Ligamentum Flavum Hypertrophy Through the LPAR1/Akt Pathway.
Topics: Animals; Apoptosis; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinases; G2 Phase Cell Cycle Checkpoints; Humans; Hypertrophy; Isoxazoles; Ligamentum Flavum; Lumbar Vertebrae; Lysophospholipids; Male; Phosphorylation; Propionates; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptors, Lysophosphatidic Acid; RNA Interference; Signal Transduction | 2018 |
Endothelin A receptor blockade improves regression of flow-induced pulmonary vasculopathy in piglets.
Topics: Angiopoietin-1; Animals; Animals, Newborn; Antihypertensive Agents; Aorta; Apoptosis; Cell Proliferation; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Hemodynamics; Hypertension, Pulmonary; Hypertrophy; Isoxazoles; Muscle, Smooth, Vascular; Pulmonary Artery; Pulmonary Circulation; Pulmonary Embolism; Receptor, Endothelin A; Receptor, TIE-2; RNA, Messenger; Sulfones; Swine; Time Factors | 2010 |
An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.
Topics: Alkaline Phosphatase; Animals; Antihypertensive Agents; Blood Coagulation; Carcinogenicity Tests; Carcinogens; Chemical and Drug Induced Liver Injury, Chronic; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Erythrocyte Indices; Female; Hypertension, Pulmonary; Hypertrophy; Isoxazoles; Liver; Liver Function Tests; Male; Mice; Mice, Inbred Strains; Organ Size; Rats; Rats, Sprague-Dawley; Risk Assessment; Species Specificity; Thiophenes | 2012 |
Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Pulmonary; Hypertrophy; Hypoxia; Isoxazoles; Male; Monocrotaline; Oxygen; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Thiophenes; Vasoconstriction; Weight Gain | 2000 |